Sulfagenix Australia Pty Ltd was established in 2013 as a wholly owned subsidiary of Sulfagenix, Inc. for the purpose of developing SG1002 in Australia for the heart failure market. Cardiovascular disease is the leading cause of death in Australia, affecting 4% of the population over the age of 45. Although there has been a gradual decline in the prevalence of heart failure patients over the past decade, an increase in patients with diabetes and obesity, along with the aging of the population is likely to reverse this trend. In addition, the Aboriginal and Torres Strait Islander peoples have incidence of heart failure 2-3 times that of the rest of the population. Dr. Henry Krum, an internationally recognized heart failure researcher from Monash University will serve as co-PI of the clinical trials.